저자의 연구 키워드

저자의 연구 키워드

#4기

#생존

#수술

#암 전이

#유방

#유방암

#화학요법

#활막 육종

#Adjuvant chemoradiotherapy

#Administration

#Anthracycline

#Antineoplastic agents

#Antitumor

#Aromatase inhibitors

#Awareness

#Axitinib

#bcl-2

#Biliary tract neoplasms

#Breast

#Breast neoplasms

#Capecitabine

#Chemoradiotherapy

#Chemotherapy

#Cisplatin

#CKD-516

#Clinical trial

#Cyclooxygenase 2

#Diabetes mellitus

#Distal cholangiocarcinoma

#Drug Screening Assays

#Drug therapy

#Elderly

#Everolimus

#Evofosfamide

#Exemestane

#First-line treatment

#Fluorescence

#Gastric Cancer

#Gemcitabine

#HER2

#Hormone receptor-positive

#Hospital Medicine

#Hospitalists

#Hypoxia

#In Situ Hybridization

#Korea

#Lanreotide

#Length of Stay

#Leptomeningeal Metastases

#Letrozole

#Metastatic breast cancer

#Metformin

#Mortality

#Neoplasm metastasis

#Neoplasms

#Neuroendocrine tumor

#Octreotide

#OPB-31121

#Oral

#Oxaliplatin

#p53

#Paclitaxel

#Pancreatectomy

#Pancreatic neoplasms

#Pancreaticoduodenectomy

#Patients

#Peptide receptor radionuclide therapy

#Perception

#P-glycoprotein

#Pharmacokinetics

#Phase 1

#Phase I

#Phase I clinical trial

#Phase II

#Phase II trial

#Prevention

#Prognosis

#Prognostic Factor

#Public health

#RNA stability

#S-1

#Sensitivity and Specificity

#Smad3

#Solid tumor

#Splenic artery

#Stage IV

#STAT3

#STAT3 inhibitor

#Stomach cancer

#Stomach neoplasms

#Sunitinib

#Surgery

#Survival

#Synovial sarcoma

#Taxane

#Temozolomide

#TH302

#Therapeutic Use

#Transforming growth factor beta

#Trastuzumab

#Tristetraprolin

#Vascular disrupting agent

#Vinorelbine

#Volition